Haleon PLC Sponsored ADR $HLN Shares Acquired by UBS Group AG

UBS Group AG grew its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 107.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 995,987 shares of the company’s stock after purchasing an additional 515,670 shares during the quarter. UBS Group AG’s holdings in Haleon were worth $10,069,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Sanctuary Advisors LLC grew its position in shares of Haleon by 9.8% in the fourth quarter. Sanctuary Advisors LLC now owns 291,629 shares of the company’s stock valued at $2,948,000 after purchasing an additional 26,095 shares during the period. Resonant Capital Advisors LLC grew its position in shares of Haleon by 12.8% in the fourth quarter. Resonant Capital Advisors LLC now owns 26,446 shares of the company’s stock valued at $267,000 after purchasing an additional 2,997 shares during the period. Concurrent Investment Advisors LLC grew its position in shares of Haleon by 44.7% in the fourth quarter. Concurrent Investment Advisors LLC now owns 22,050 shares of the company’s stock valued at $223,000 after purchasing an additional 6,815 shares during the period. OLD National Bancorp IN grew its position in shares of Haleon by 28.7% in the fourth quarter. OLD National Bancorp IN now owns 20,022 shares of the company’s stock valued at $202,000 after purchasing an additional 4,463 shares during the period. Finally, HB Wealth Management LLC grew its position in shares of Haleon by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 133,581 shares of the company’s stock valued at $1,351,000 after purchasing an additional 5,857 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on HLN. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Finally, Argus upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Haleon presently has an average rating of “Moderate Buy” and a consensus target price of $13.40.

Haleon Price Performance

Shares of HLN stock opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm’s 50-day moving average is $9.74 and its two-hundred day moving average is $9.96. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company has a market capitalization of $39.81 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 2.04 and a beta of 0.15.

Haleon (NYSE:HLN) last issued its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion for the quarter. Analysts predict that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Haleon Announces Dividend

The business also recently declared a dividend, which was paid on Thursday, May 14th. Stockholders of record on Friday, April 10th were paid a $0.1307 dividend. This represents a dividend yield of 266.0%. The ex-dividend date of this dividend was Friday, April 10th. Haleon’s payout ratio is 64.10%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.